AzTrials
AzTrials

Acute Respiratory Distress Syndrome (ARDS)Masi-ARDSNCT06667375

Conventional Versus Automated Bag-based Mechanical Ventilator to Support ARDS Patients

An observational study of Acute Respiratory Distress Syndrome (ARDS), run by Fanny Lys Casado Pena at 1 site in Peru.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study evaluates the extubation success and compares the survival rate in patients with signs of Covid-19 intubated with Masi, a novel type of mechanical ventilator, or with other conventional ventilators admitted in the ICU of a reference hospital in Lima, Peru between January and August 2021. Read more about this study

Who is it for?
Ages 18 years and older
How many people
87 participants
Where
1 sitePeru
Study dates
19 Jan 2021to 20 Dec 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Data from patients that were diagnosed with Covid-19, intubated and connected to a mechanical ventilator in the ICU between January 19, 2021 to August 27, 2021 which coincides with the second Peruvian wave of the Covid-19 pandemics in the Hospital Vitarte II in Lima

Who may be able to join

  • Patients hospitalized to ICU requiring mechanical ventilation during COVID-19 pandemic
  • Over 18 years old

Who cannot join

  • None

Trial locations and contacts

1 site in 1 country.

Peru1 site
  • Pontificia Universidad Católica del Perú

    Lima, 15023

Other trials in Peru

About this study

Official title: Description of the Performance of the "Masi" Mechanical Ventilator in a Hospital in Lima: Case Series

This study evaluates the extubation success and compares the survival rate in patients with signs of Covid-19 intubated with Masi, a novel type of mechanical ventilator, or with other conventional ventilators admitted in the ICU of a reference hospital in Lima, Peru between January and August 2021. The Masi mechanical ventilator works by automating a resuscitation bag with promising preclinical results. The key features of Masi are its low manufacturing cost, low dependence on a supply of high volumes of oxygen, low oxygen consumption, flexibility between non-invasive and invasive ventilation, and extended range of working environmental altitudes compared to commercially available ventilators. A retrospective study of variables and outcomes was done. The main goal of this study is to compare the survival rate of respiratory failure patients supported either with Masi or conventional ventilators at Hospital Vitarte II in Lima between January and August 2021.

Read the detailed description

The translation of novel technologies for Intensive Care Units (ICU) including mechanical ventilators has been mostly about incremental improvements through increasing features assuming the presence of highly trained personnel and dedicated infrastructure such as permanent power supply and high oxygen flow. Despite the long history of use of mechanical ventilators, the Covid-19 pandemic demanded innovation to meet worldwide demands for this type of life support equipment. The inadequacy of the commercially available ventilators has been mostly attributed to weak fabrication and supply chains and inconsistencies between the required sanitary infrastructure and human resources available for which most commercial ventilators have been designed. Diverse approaches addressed the design and development of low-cost and more available mechanical ventilators worldwide achieving various levels of clinical implementation.

In Peru, the Masi (companion in Quechua) ventilator was developed based on concepts of the MIT Emergency Ventilator (MIT E-Vent) by automating a resuscitation bag. The Masi initiative showed promising pre-clinical results that allowed the production of more than 250 units under an exceptional permit to be used clinically in Peru only when no other ventilators were available. The key features of this technology are its low manufacturing cost, low oxygen consumption, flexibility between non-invasive and invasive ventilation, and extended range of working environmental altitudes compared to commercially available ventilators. Clinical characteristics, blood chemistry information, respiratory parameters, and survival rates were analyzed for 77 patients (42 ventilated by Masi, 35 ventilated by commercial ventilators).

This is an observational retrospective cohort study. The study protocol was approved by the Research Ethics Committee for Life Sciences and Technology of the PUCP (002-2021-CEICVyTech/PUCP) on September 23, 2021. A total of one hundred and three (103) patients were admitted to the ICU between January 19, 2021 until August 27, 2021, which coincides with the second Peruvian wave of the Covid-19 pandemic in the Hospital Vitarte II in Lima, Peru. Data from patients who were diagnosed with Covid-19, with signs of Acute Respiratory Distress Syndrome (ARDS), intubated, and connected to a mechanical ventilator in the ICU were de-identified for this study. From the 132 variables collected into the Electronic Health Records, only 120 selected variables were transcribed into an electronic database (Microsoft Excel V). The data was standardized and entered by a physician trained in Good Clinical Practice (Data Entry Investigator) following a Data Dictionary.

After data cleanup, this study retrospectively analyzed data from eighty-seven (87) patients who had a positive Covid-19 diagnosis and used a mechanical ventilator machine. According to the Peruvian regulatory agency, DIGEMID, Masi was indicated only when no conventional ventilator was available, and a patient needed one as determined by the ICU physician. The physicians used their criteria to prescribe Masi or other available ventilator brands.

During the described period, the ICU of the Hospital Vitarte II had seven beds and four conventional ventilators: Evolution (EVL100001-T-NF), Vela (16532-07), Newport (e360) and Dragger (Savina 300). Eight new individually validated ventilators known as Masi were provided to the ICU, and the medical personnel were trained regarding its clinical use. This device was approved to be used in Peru during the sanitary emergency by the local competent authority: Dirección General de Medicamentos, Insumos y Dispositivos Médicos (DIGEMID, Spanish acronym) based on preclinical evidence of safety.

To avoid bias derived from the convenience sampling of a single-site study, the Data Entry Investigator reviewed the medical charts corresponding to every patient (n=103) admitted into ICU at the site during the study range across Masi before selecting the charts to be included. A selection was made from the initial 132 variables recorded based on relevance for the present study. Variables from the initial database were uploaded into R studio. The variables and values were reviewed by two independent data analysts and queried to the data entry assistant when necessary. The dataset was cleaned up, and variables were normalized and categorized. Each variable was evaluated with a univariate analysis followed by a bivariate analysis comparing different results between pre- and post-intubation, and post and last-intubation measurements. The main factors used for comparison were the respiratory parameters before and after the intubation between the mechanical ventilators Masi versus conventional. An additional analysis was done to compare survival rates by using the Kaplan-Meier estimator and COX analysis. A sensitivity analysis was done to each model to evaluate suitability for a non- parametric and semi-parametric test.

Keywords
Ventilators, Medical devices,, Data analysis, Technological innovation
Medical subject headings
Respiratory Distress Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06667375
Study groupRoleWhat they receive
MasiPatients who were diagnosed with Covid-19, with signs of Acute Respiratory Distress Syndrome (ARDS), intubated, and connected to an automated-bag mechanical ventilator in the ICU
ConventionalPatients who were diagnosed with Covid-19, with signs of Acute Respiratory Distress Syndrome (ARDS), intubated, and connected to a commercial mechanical ventilator in the ICU

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. ICU discharge status

    After being in the ventilator in the ICU what happened at extubation or censoring time.

    Measured: Patients were followed 15 days (median)

Secondary outcomes (5)
  1. Ventilator parameter: Oxygen Saturation (%)

    Comparing Oxygen Saturation(%) between ventilators.

    Measured: Patients were followed up 15 days (median)

  2. Ventilator parameter: Respiratory rate (breaths/minute)

    By comparing Respiratory rates between ventilators.

    Measured: Patients were followed up 15 days (median)

  3. Ventilator parameter: PaO2/FiO2 ratio

    Comparing PaO2/FiO2 ratio between ventilators.

    Measured: Patients were followed up 15 days (median)

  4. Ventilator parameters: Tidal volumen (mL)

    Comparing Tidal volumen between ventilators

    Measured: Patients were followed up 15 days (median)

  5. Ventilator parameters: PIP (mmHg)

    Comparing PIP values between ventilators.

    Measured: Patients were followed up 15 days (median)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Oct 2024
  2. Study start19 Jan 2021
  3. Primary completion27 Aug 2021
  4. Study completion20 Dec 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
87 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06667375
Sponsor's protocol ID
002-2021-CEICVyTech/PUCP
Acronym
Masi-ARDS
Status last verified
Oct 2024
First submitted
28 Oct 2024
Last updated
31 Oct 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: Pending to confirm with local team and local laws what IPD can be shared. An URL is also required once we check Yes; we dont have any URL ready.

Questions about this trial

What is this clinical trial studying?

An observational study of Acute Respiratory Distress Syndrome (ARDS), run by Fanny Lys Casado Pena at 1 site in Peru.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 31 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Peru. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

ICU discharge status (time frame: Patients were followed 15 days (median)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Oct 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in